Network quantification of EGFR signaling unveils potential for targeted combination therapy.
about
Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistanceRegulatory network features in Listeria monocytogenes-changing the way we talkDiscovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical ModelingClinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model.KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model.Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.Computational systems biology approaches to anti-angiogenic cancer therapeutics.Disentangling the Complexity of HGF Signaling by Combining Qualitative and Quantitative Modeling.ASSIGN: context-specific genomic profiling of multiple heterogeneous biological pathwaysGenomic classification of the RAS network identifies a personalized treatment strategy for lung cancerIntegrative analysis of the microRNA-mRNA response to radiochemotherapy in primary head and neck squamous cell carcinoma cellsSystematic synergy modeling: understanding drug synergy from a systems biology perspective.A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT.Technical Insights into Highly Sensitive Isolation and Molecular Characterization of Fixed and Live Circulating Tumor Cells for Early Detection of Tumor Invasion.Predictive Modeling of Drug Treatment in the Area of Personalized Medicine.Prediction of treatment efficacy for prostate cancer using a mathematical model.Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway.Protein abundance of AKT and ERK pathway components governs cell type-specific regulation of proliferation.Integrative radiation systems biology.Consequences of feedback in signal transduction for targeted therapies.Rationally designed treatment for metastatic colorectal cancer: current drug development strategiesCancer systems biology: embracing complexity to develop better anticancer therapeutic strategies.Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.Logic Modeling in Quantitative Systems Pharmacology.EGFR signaling pathways are wired differently in normal 184A1L5 human mammary epithelial and MDA-MB-231 breast cancer cells.Integrating network reconstruction with mechanistic modeling to predict cancer therapies.An immediate-late gene expression module decodes ERK signal durationSimultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancerA novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy.mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.Cell signaling as a cognitive process.EGF receptor family: twisting targets for improved cancer therapies.Synergy evaluation by a pathway-pathway interaction network: a new way to predict drug combination.Parallel feedback loops control the basal activity of the HOG MAPK signaling cascade.Profiling the MAPK/ERK dependent and independent activity regulated transcriptional programs in the murine hippocampus in vivo.Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axisFluorescence resonance energy transfer based quantitative analysis of feedforward and feedback loops in epidermal growth factor receptor signaling and the sensitivity to molecular targeting drugs.BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.
P2860
Q26795609-8EA49024-B4BD-4A05-A8AC-86F745B8FCE1Q27004898-C956F9D0-CA47-4432-863C-21FB690A1C4EQ28547862-CD8F99F1-0B47-4640-B143-19C862C2310AQ33767369-8C20C17F-10B1-489E-BDEC-F94349866848Q34039936-E2FC5FDA-6A69-420D-B29B-3D2E2C05E11BQ34489987-407AFFF1-E1D9-459D-BEE1-3BB57D0E306BQ35108084-ACB8A286-259B-45D7-A577-9601D2E3E818Q35612549-2690D487-EE9E-419C-A257-959ED9557AAAQ35646230-B50E4F96-902A-4160-9BBA-5EA4E9E905AAQ35670290-EF7A9B2C-7205-4A92-9603-9D1F2B1DE266Q35761391-D94BB196-7797-48C0-BDF3-43D225915DAAQ35777950-3F2C2150-9CBD-4051-BF17-17CFA8C29A44Q36052565-F0C9306D-07E9-4EEF-9BD4-3EC5BE1E7734Q36242936-510996F2-99C7-4530-B694-4180AA095D14Q36351777-2CB13935-86E2-4F71-9B87-3B29BC73DF2DQ36574383-C4F9C12D-6404-4919-B071-3BCAB00AF021Q37593264-5F42A972-CEA8-4E0B-AE25-E9A190CD7017Q37626301-92654F2F-C416-44DF-AA00-AFA64E338069Q38177390-A3B6E2A4-505E-4A3D-B442-57B4EE3BBC51Q38238604-6DDF5950-3695-4D2D-B536-9668C4E45866Q38240841-55A1E7E7-F06C-4BBA-8589-766010076A05Q38249099-3C1D4C71-41A1-439C-950F-A67FD62553DAQ38390840-04F468D6-B620-4130-AA66-927CF5CBFEE9Q38691620-05D13DE1-88D2-49AB-88B7-24CF972E337BQ38709632-04A3A1DB-4D40-4051-807C-D734153B9C39Q38729295-0C297501-16C3-4B8C-BBA5-0B80E3C506EEQ38806418-D4DA1C71-FCF3-41D8-B5E7-96F8E0C24326Q38825141-14AE8E3A-93CC-442B-AA9B-E2A1335D42B5Q38868595-6A81D2BA-F00C-4800-8D48-CA1DCE1E7471Q38902585-79F4B3A9-D346-43F5-8594-6F7892712AD8Q38907215-C6CF7533-9DEC-4C3C-8211-36D6B6A5CBE2Q38911597-2A59B4FD-8396-48C6-8997-B8EB3B85C0B3Q39110198-26C3E421-44B5-4F57-A52B-3230B7FEBF79Q39228711-444CA45C-9E56-4FB8-8858-0BEA3E4B0C57Q40188819-BE5FB880-17B3-4A7F-B9CA-57B49DC32603Q41312755-B44089DA-3081-4DF2-8340-4176053307E1Q41847377-25262C44-CEC5-4523-A5E4-486130C9AE3DQ42106395-7ED3B157-2D7C-45C6-A058-74724227775EQ45715391-904AD569-9EAF-46A5-8060-DD83A9A0C07EQ47736865-CC8F0E09-D67C-4EAF-96E6-CDF7C1B19900
P2860
Network quantification of EGFR signaling unveils potential for targeted combination therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Network quantification of EGFR ...... targeted combination therapy.
@en
Network quantification of EGFR ...... targeted combination therapy.
@nl
type
label
Network quantification of EGFR ...... targeted combination therapy.
@en
Network quantification of EGFR ...... targeted combination therapy.
@nl
prefLabel
Network quantification of EGFR ...... targeted combination therapy.
@en
Network quantification of EGFR ...... targeted combination therapy.
@nl
P2093
P2860
P50
P356
P1476
Network quantification of EGFR ...... r targeted combination therapy
@en
P2093
Anja Sieber
Christine Sers
Franziska Witzel
Leanne Berry
Mark Merchant
Pawel Durek
Raphaela Fritsche-Guenther
Yibing Yan
P2860
P356
10.1038/MSB.2013.29
P577
2013-01-01T00:00:00Z